A clinical trial is underway to evaluate the safety and efficacy of daily Rifapentine combined with Isoniazid for tuberculosis prevention in children under 13, including those with HIV.

RegulatoryJune 27, 2026

FDA Grants Approval for Rifapentine ANDA217042 by Macleods Pharmaceuticals

The FDA has granted approval for the ANDA217042 application for Rifapentine submitted by Macleods Pharmaceuticals.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Macleods Pharmaceuticals — Rifapentine

June 27, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Antitubercular →

Infectious Disease →

Infectious Disease · Antitubercular →

Tuberculosis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.